Stock Analiz

Quantum Biopharma Ltd. QNTM

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.61Market cap $10M
Open the interactive analysis →

Quantum Biopharma Ltd. (QNTM) is a healthcare company listed in the US with a market value of about $10M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -59%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 99% below the current price.

About Quantum Biopharma

Quantum Biopharma is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 4 years in our data.

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B1.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-274.8%
Shareholder yield0.0%
Intrinsic value vs. price−99%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-19776.4%
ROIC (5-yr avg.)-59.0%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 4 years

Fiscal year2022202120202019
Revenue———$197860
Net income-$24M-$35M-$32M-$39M
Free cash flow-$28M-$21M-$19M—
EPS (diluted)$-3.67$-5.49$-4.95$-6.09
Net margin———-19776.4%
ROIC-71.0%-49.2%-66.8%-49.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $12.22, 659% above the current price; targets range from $12.22 to $12.22; the consensus rating is “none”; expected EPS is $-2.58 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Quantum Biopharma stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 99% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Quantum Biopharma pay a dividend?

Not currently.

Is Quantum Biopharma a good stock to buy?

We do not give buy or sell advice. Quantum Biopharma scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.